ArticleEJHaem2020

Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.

Elizabeth H Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.